Clinical Trials Browser

Phase 1/2 × Lymphoma, Follicular × venetoclax × Clear all

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT02956382 2025-07-18

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Phase 1/2 Completed

24 enrolled 18 charts

Lymphoid

Lymphoma, Lymphoma, Follicular, Recurrence

NCT03583424 2025-05-14

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1/2 Completed

19 enrolled 12 charts

Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT03980171 2024-07-29

LEVERAGE

Phase 1/2 Active not recruiting

50 enrolled

Lymphoid

Lymphoma, Follicular

NCT04722601 2024-05-16

A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma

Phase 1/2 Terminated

2 enrolled 7 charts

Lymphoid

Lymphoma, Follicular

NCT03135262 2021-12-07

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Terminated

29 enrolled 18 charts

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Clinical Trials

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

LEVERAGE

A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)